Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | TP53 | P04637 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283407 | 0.92 | DRD3 (0.46) | MAPTTP53LMNABRD4CREBBP | |
| SCHEMBL1284146 | 0.90 | DRD2 (0.45) | MAPTTP53LMNABRD4CREBBP | |
| SCHEMBL1614049 | 0.89 | DRD3 (0.46) | MAPTTP53LMNABRD4CREBBP | |
| SCHEMBL1614727 | 0.88 | MAPT (0.54) | MAPTTP53LMNABRD4CREBBP | |
| SCHEMBL1614104 | 0.87 | SMN1; SMN2 (0.53) | MAPTTP53LMNABRD4CREBBP | |
| SCHEMBL1615081 | 0.87 | TP53 (0.47) | MAPTTP53BRD4CREBBPSMN1; SMN2 | |
| SCHEMBL1282934 | 0.86 | DRD3 (0.45) | MAPTTP53LMNACNR1CNR2 | |
| SCHEMBL1615303 | 0.85 | MCHR1 (0.52) | MAPTTP53BRD4CREBBPSMN1; SMN2 | |
| SCHEMBL1614766 | 0.85 | SMN1; SMN2 (0.52) | MAPTTP53BRD4CREBBPSMN1; SMN2 | |
| SCHEMBL1282449 | 0.81 | DRD3 (0.50) | MAPTTP53LMNABRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | MAPT 430/4885TP53 238/4885LMNA 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.